A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis
The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gu, Chunping [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
Leupeptin (Pubchem CID: 72429) Lipopolysaccharide (Pubchem CID: 11970143) Aprotinin (Pubchem CID: 16130295) Pepstatin (Pubchem CID: 5478883) |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Mexican student-teachers’ “English” language praxicum: Decolonizing attempts - López-Gopar, Mario E. ELSEVIER, 2022, EJP, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:729 ; year:2014 ; day:15 ; month:04 ; pages:22-29 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejphar.2014.01.019 |
|---|
| Katalog-ID: |
ELV023064870 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023064870 | ||
| 003 | DE-627 | ||
| 005 | 20230625140633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2014.01.019 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014020000026.pica |
| 035 | |a (DE-627)ELV023064870 | ||
| 035 | |a (ELSEVIER)S0014-2999(14)00020-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 370 |q VZ |
| 084 | |a 5,3 |2 ssgn | ||
| 100 | 1 | |a Gu, Chunping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. | ||
| 520 | |a The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. | ||
| 650 | 7 | |a Leupeptin (Pubchem CID: 72429) |2 Elsevier | |
| 650 | 7 | |a Lipopolysaccharide (Pubchem CID: 11970143) |2 Elsevier | |
| 650 | 7 | |a G418 (Pubchem CID: 123865) |2 Elsevier | |
| 650 | 7 | |a PMSF (Pubchem CID: 4784) |2 Elsevier | |
| 650 | 7 | |a Aprotinin (Pubchem CID: 16130295) |2 Elsevier | |
| 650 | 7 | |a Pepstatin (Pubchem CID: 5478883) |2 Elsevier | |
| 650 | 7 | |a DAPI (Pubchem CID: 2954) |2 Elsevier | |
| 650 | 7 | |a BAY 11-7082 (Pubchem CID: 5353431) |2 Elsevier | |
| 650 | 7 | |a MTT (Pubchem CID: 64965) |2 Elsevier | |
| 650 | 7 | |a Sodium fluoride (Pubchem CID: 5235) |2 Elsevier | |
| 700 | 1 | |a Yu, Fang-Lin |4 oth | |
| 700 | 1 | |a Yu, Le |4 oth | |
| 700 | 1 | |a He, Xiao-Yang |4 oth | |
| 700 | 1 | |a Zhong, Desheng |4 oth | |
| 700 | 1 | |a He, Longgang |4 oth | |
| 700 | 1 | |a Lv, Longyun |4 oth | |
| 700 | 1 | |a Xie, Lan |4 oth | |
| 700 | 1 | |a Liu, Shuwen |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a López-Gopar, Mario E. ELSEVIER |t Mexican student-teachers’ “English” language praxicum: Decolonizing attempts |d 2022 |d EJP |g New York, NY [u.a.] |w (DE-627)ELV008405875 |
| 773 | 1 | 8 | |g volume:729 |g year:2014 |g day:15 |g month:04 |g pages:22-29 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejphar.2014.01.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 729 |j 2014 |b 15 |c 0415 |h 22-29 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
c g cg |
|---|---|
| matchkey_str |
guchunpingyufanglinyulehexiaoyangzhongde:2014----:nvlyteidbnoylotdeeinnnlglf06teutsiooyacaienueifamtrrsosirw67a |
| hierarchy_sort_str |
2014transfer abstract |
| publishDate |
2014 |
| allfields |
10.1016/j.ejphar.2014.01.019 doi GBVA2014020000026.pica (DE-627)ELV023064870 (ELSEVIER)S0014-2999(14)00020-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 370 VZ 5,3 ssgn Gu, Chunping verfasserin aut A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) Elsevier Yu, Fang-Lin oth Yu, Le oth He, Xiao-Yang oth Zhong, Desheng oth He, Longgang oth Lv, Longyun oth Xie, Lan oth Liu, Shuwen oth Enthalten in Elsevier López-Gopar, Mario E. ELSEVIER Mexican student-teachers’ “English” language praxicum: Decolonizing attempts 2022 EJP New York, NY [u.a.] (DE-627)ELV008405875 volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 https://doi.org/10.1016/j.ejphar.2014.01.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 729 2014 15 0415 22-29 8 045F 610 |
| spelling |
10.1016/j.ejphar.2014.01.019 doi GBVA2014020000026.pica (DE-627)ELV023064870 (ELSEVIER)S0014-2999(14)00020-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 370 VZ 5,3 ssgn Gu, Chunping verfasserin aut A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) Elsevier Yu, Fang-Lin oth Yu, Le oth He, Xiao-Yang oth Zhong, Desheng oth He, Longgang oth Lv, Longyun oth Xie, Lan oth Liu, Shuwen oth Enthalten in Elsevier López-Gopar, Mario E. ELSEVIER Mexican student-teachers’ “English” language praxicum: Decolonizing attempts 2022 EJP New York, NY [u.a.] (DE-627)ELV008405875 volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 https://doi.org/10.1016/j.ejphar.2014.01.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 729 2014 15 0415 22-29 8 045F 610 |
| allfields_unstemmed |
10.1016/j.ejphar.2014.01.019 doi GBVA2014020000026.pica (DE-627)ELV023064870 (ELSEVIER)S0014-2999(14)00020-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 370 VZ 5,3 ssgn Gu, Chunping verfasserin aut A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) Elsevier Yu, Fang-Lin oth Yu, Le oth He, Xiao-Yang oth Zhong, Desheng oth He, Longgang oth Lv, Longyun oth Xie, Lan oth Liu, Shuwen oth Enthalten in Elsevier López-Gopar, Mario E. ELSEVIER Mexican student-teachers’ “English” language praxicum: Decolonizing attempts 2022 EJP New York, NY [u.a.] (DE-627)ELV008405875 volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 https://doi.org/10.1016/j.ejphar.2014.01.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 729 2014 15 0415 22-29 8 045F 610 |
| allfieldsGer |
10.1016/j.ejphar.2014.01.019 doi GBVA2014020000026.pica (DE-627)ELV023064870 (ELSEVIER)S0014-2999(14)00020-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 370 VZ 5,3 ssgn Gu, Chunping verfasserin aut A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) Elsevier Yu, Fang-Lin oth Yu, Le oth He, Xiao-Yang oth Zhong, Desheng oth He, Longgang oth Lv, Longyun oth Xie, Lan oth Liu, Shuwen oth Enthalten in Elsevier López-Gopar, Mario E. ELSEVIER Mexican student-teachers’ “English” language praxicum: Decolonizing attempts 2022 EJP New York, NY [u.a.] (DE-627)ELV008405875 volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 https://doi.org/10.1016/j.ejphar.2014.01.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 729 2014 15 0415 22-29 8 045F 610 |
| allfieldsSound |
10.1016/j.ejphar.2014.01.019 doi GBVA2014020000026.pica (DE-627)ELV023064870 (ELSEVIER)S0014-2999(14)00020-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 370 VZ 5,3 ssgn Gu, Chunping verfasserin aut A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) Elsevier Yu, Fang-Lin oth Yu, Le oth He, Xiao-Yang oth Zhong, Desheng oth He, Longgang oth Lv, Longyun oth Xie, Lan oth Liu, Shuwen oth Enthalten in Elsevier López-Gopar, Mario E. ELSEVIER Mexican student-teachers’ “English” language praxicum: Decolonizing attempts 2022 EJP New York, NY [u.a.] (DE-627)ELV008405875 volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 https://doi.org/10.1016/j.ejphar.2014.01.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 729 2014 15 0415 22-29 8 045F 610 |
| language |
English |
| source |
Enthalten in Mexican student-teachers’ “English” language praxicum: Decolonizing attempts New York, NY [u.a.] volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 |
| sourceStr |
Enthalten in Mexican student-teachers’ “English” language praxicum: Decolonizing attempts New York, NY [u.a.] volume:729 year:2014 day:15 month:04 pages:22-29 extent:8 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Leupeptin (Pubchem CID: 72429) Lipopolysaccharide (Pubchem CID: 11970143) G418 (Pubchem CID: 123865) PMSF (Pubchem CID: 4784) Aprotinin (Pubchem CID: 16130295) Pepstatin (Pubchem CID: 5478883) DAPI (Pubchem CID: 2954) BAY 11-7082 (Pubchem CID: 5353431) MTT (Pubchem CID: 64965) Sodium fluoride (Pubchem CID: 5235) |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Mexican student-teachers’ “English” language praxicum: Decolonizing attempts |
| authorswithroles_txt_mv |
Gu, Chunping @@aut@@ Yu, Fang-Lin @@oth@@ Yu, Le @@oth@@ He, Xiao-Yang @@oth@@ Zhong, Desheng @@oth@@ He, Longgang @@oth@@ Lv, Longyun @@oth@@ Xie, Lan @@oth@@ Liu, Shuwen @@oth@@ |
| publishDateDaySort_date |
2014-01-15T00:00:00Z |
| hierarchy_top_id |
ELV008405875 |
| dewey-sort |
3610 |
| id |
ELV023064870 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023064870</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625140633.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejphar.2014.01.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014020000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023064870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0014-2999(14)00020-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">370</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">5,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gu, Chunping</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Leupeptin (Pubchem CID: 72429)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipopolysaccharide (Pubchem CID: 11970143)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">G418 (Pubchem CID: 123865)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PMSF (Pubchem CID: 4784)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aprotinin (Pubchem CID: 16130295)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pepstatin (Pubchem CID: 5478883)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DAPI (Pubchem CID: 2954)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BAY 11-7082 (Pubchem CID: 5353431)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MTT (Pubchem CID: 64965)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sodium fluoride (Pubchem CID: 5235)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Fang-Lin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Le</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">He, Xiao-Yang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhong, Desheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">He, Longgang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lv, Longyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xie, Lan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Shuwen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">López-Gopar, Mario E. ELSEVIER</subfield><subfield code="t">Mexican student-teachers’ “English” language praxicum: Decolonizing attempts</subfield><subfield code="d">2022</subfield><subfield code="d">EJP</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008405875</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:729</subfield><subfield code="g">year:2014</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:22-29</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejphar.2014.01.019</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">729</subfield><subfield code="j">2014</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">22-29</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Gu, Chunping |
| spellingShingle |
Gu, Chunping ddc 610 ddc 370 ssgn 5,3 Elsevier Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis |
| authorStr |
Gu, Chunping |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008405875 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 370 - Education |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 370 VZ 5,3 ssgn A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) Elsevier |
| topic |
ddc 610 ddc 370 ssgn 5,3 Elsevier Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) |
| topic_unstemmed |
ddc 610 ddc 370 ssgn 5,3 Elsevier Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) |
| topic_browse |
ddc 610 ddc 370 ssgn 5,3 Elsevier Leupeptin (Pubchem CID: 72429) Elsevier Lipopolysaccharide (Pubchem CID: 11970143) Elsevier G418 (Pubchem CID: 123865) Elsevier PMSF (Pubchem CID: 4784) Elsevier Aprotinin (Pubchem CID: 16130295) Elsevier Pepstatin (Pubchem CID: 5478883) Elsevier DAPI (Pubchem CID: 2954) Elsevier BAY 11-7082 (Pubchem CID: 5353431) Elsevier MTT (Pubchem CID: 64965) Elsevier Sodium fluoride (Pubchem CID: 5235) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f l y fly l y ly x y h xyh d z dz l h lh l l ll l x lx s l sl |
| hierarchy_parent_title |
Mexican student-teachers’ “English” language praxicum: Decolonizing attempts |
| hierarchy_parent_id |
ELV008405875 |
| dewey-tens |
610 - Medicine & health 370 - Education |
| hierarchy_top_title |
Mexican student-teachers’ “English” language praxicum: Decolonizing attempts |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008405875 |
| title |
A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis |
| ctrlnum |
(DE-627)ELV023064870 (ELSEVIER)S0014-2999(14)00020-X |
| title_full |
A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis |
| author_sort |
Gu, Chunping |
| journal |
Mexican student-teachers’ “English” language praxicum: Decolonizing attempts |
| journalStr |
Mexican student-teachers’ “English” language praxicum: Decolonizing attempts |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
22 |
| author_browse |
Gu, Chunping |
| container_volume |
729 |
| physical |
8 |
| class |
610 610 DE-600 370 VZ 5,3 ssgn |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gu, Chunping |
| doi_str_mv |
10.1016/j.ejphar.2014.01.019 |
| dewey-full |
610 370 |
| title_sort |
a novel synthetic dibenzocyclooctadiene lignan analog xlyf-104-6 attenuates lipopolysaccharide-induced inflammatory response in raw264.7 macrophage cells and protects balb/c mice from sepsis |
| title_auth |
A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis |
| abstract |
The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. |
| abstractGer |
The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. |
| abstract_unstemmed |
The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis |
| url |
https://doi.org/10.1016/j.ejphar.2014.01.019 |
| remote_bool |
true |
| author2 |
Yu, Fang-Lin Yu, Le He, Xiao-Yang Zhong, Desheng He, Longgang Lv, Longyun Xie, Lan Liu, Shuwen |
| author2Str |
Yu, Fang-Lin Yu, Le He, Xiao-Yang Zhong, Desheng He, Longgang Lv, Longyun Xie, Lan Liu, Shuwen |
| ppnlink |
ELV008405875 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejphar.2014.01.019 |
| up_date |
2024-07-06T17:53:18.135Z |
| _version_ |
1803853127363854336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023064870</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625140633.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejphar.2014.01.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014020000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023064870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0014-2999(14)00020-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">370</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">5,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gu, Chunping</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The wide range of inflammation mechanisms under control by NF-κB makes this pathway as an attractive target for new anti-inflammatory drugs. Herein, we showed that a new dibenzocyclooctadiene lignan analog XLYF-104-6, with a chemical name of 1,2,3,10,11-pentamethoxydibenzocycloocta-6,7-[c] pyrrole-1,3-dione, inhibited lipopolysaccharide (LPS)-induced NF-κB activation in RAW264.7 cells through preventing IκBα degradation and p65 nuclear translocation. The inhibitory activity of this compound on NF-κB activation contributes to the reduction of LPS-induced TNF-α and IL-6 productions. Notably, XLYF-104-6 suppressed LPS-induced iNOS expression and NO production in a NF-κB independent manner, since IKK inhibitor BAY 11-7082 has failed to exert similar inhibitory effect on iNOS expression and NO production. In addition, XLFY-104-6 also exerted anti-inflammatory action in endotoxemic mice by decreasing plasma LPS-induced TNF-α and IL-1β levels as well as increasing plasma LPS-induced IL-10 concentrations. These findings suggest XLYF-104-6 could act as a leading compound for developing a potential anti-inflammatory drug.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Leupeptin (Pubchem CID: 72429)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipopolysaccharide (Pubchem CID: 11970143)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">G418 (Pubchem CID: 123865)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PMSF (Pubchem CID: 4784)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Aprotinin (Pubchem CID: 16130295)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pepstatin (Pubchem CID: 5478883)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DAPI (Pubchem CID: 2954)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BAY 11-7082 (Pubchem CID: 5353431)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MTT (Pubchem CID: 64965)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sodium fluoride (Pubchem CID: 5235)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Fang-Lin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Le</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">He, Xiao-Yang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhong, Desheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">He, Longgang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lv, Longyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xie, Lan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Shuwen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">López-Gopar, Mario E. ELSEVIER</subfield><subfield code="t">Mexican student-teachers’ “English” language praxicum: Decolonizing attempts</subfield><subfield code="d">2022</subfield><subfield code="d">EJP</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008405875</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:729</subfield><subfield code="g">year:2014</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:22-29</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejphar.2014.01.019</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">729</subfield><subfield code="j">2014</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">22-29</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401107 |